EVALUATION OF THE SAFETY AND THROMBOLYTIC EFFECTS OF ASCENDING DOSES OF TS23 (DS-9231) IN SUBJECTS WITH INTERMEDIATE-RISK (SUB-MASSIVE) ACUTE PULMONARY EMBOLISM

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Abdul Khan
Sponsor
Translational Sciences Inc
Unit
COM Phx Internal Medicine